The World Health Organization (WHO) has endorsed the vaccine. “Covaxin” (Covaxin) of Bharat Biotech, an Indian drug manufacturer for use in the prevention of COVID-19 is an emergency This will allow the vaccine to be accepted as a viable vaccine in many poor countries.
WHO revealed via Twitter account that The WHO Technical Advisory Panel determined that the benefits of the kovacin vaccine outweigh the risks and meet WHO standards for protection against COVID-19.
Additionally, the WHO’s expert panel advising on immunization strategies recommends two doses of the kovacin vaccine with four-week intervals for people aged 18 years and over. Advice of Parat Biotech
However, the WHO said it had not yet recommended the use of kovacin in children. and the currently available use data for pregnant women are insufficient to assess safety or efficacy.
The kovacin vaccine was approved for emergency use in India in January this year before the final phase of the trial. The results of the experiment found that Vaccines are 78% effective at preventing serious illness from COVID-19.
The WHO decision is expected to allow millions of Indians who have received the kovacin vaccine to leave the country.
in addition Kovacin It is the eighth COVID-19 vaccine approved for emergency use by the WHO, after AstraZeneca/Oxford, Pfizer/Bioentech, Kowichi. Old, Johnson & Johnson, Moderna, Sino Farm and Sinovac.
.
